The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging
Open accessAbstract
A mouse model of glioblastoma multiforme was used to determine the accumulation of a targeted contrast agent in tumor vessels. The contrast agent, consisting of superparamagnetic iron oxide coated with dextran, was functionalized with an anti-insulin-like-growth-factor binding protein 7 (anti-IGFBP7) single domain antibody. The near infrared marker, Cy5.5, was also attached for an in vivo fluorescence study. A 9.4T magnetic resonance imaging (MRI) system was used for in vivo studies on days 10 and 11 following tumor inoculation. T(2) relaxation time was used to measure the accumulation of the contrast agent in the tumor. Changes in tumor to brain contrast because of active targeting were compared with a nontargeted contrast agent. Effective targeting was confirmed with near infrared measurements and fluorescent microscopic analysis. The results showed that there was a statistically significant (P < .01) difference in normalized T(2) between healthy brain and tumor tissue 10 min, 1 h, and 2 h point postinjection of the anti-IGFBP7 single domain antibody targeted and nontargeted iron oxide nanoparticles. A statistical difference remained in animals treated with targeted nanoparticles 24 h postinjection only. The MRI, near infrared imaging, and fluorescent microscopy studies showed corresponding spatial and temporal changes. We concluded that the developed anti-IGFBP7-iron oxide single domain antibody-targeted MRI contrast agent selectively binds to abnormal vessels within a glioblastoma. T(2)-weighted MRI and near infrared imaging are able to detect the targeting effects in brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, Y.-X. J., Hussain, S. M., & Krestin, G. P. (2001) · European Radiology · doi:10.1007/s003300100908 · Cited by 1,381
Cited by
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles
Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00541h · Cited by 830
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 605
Superparamagnetic Iron Oxide Nanoparticles—Current and Prospective Medical Applications
Dulińska-Litewka, J., Łazarczyk, A., Hałubiec, P., Szafrański, O., Karnas, K., & Karewicz, A. (2019) · Materials · doi:10.3390/ma12040617 · Cited by 580
Multifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 349
Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications
Zarschler, K., Rocks, L., Licciardello, N., Boselli, L., Polo, E., Garcia, K. P., De Cola, L., Stephan, H., & Dawson, K. A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.02.019 · Cited by 303
Metadata
- Authors
- Tomanek, B., Iqbal, U., Blasiak, B., Abulrob, A., Albaghdadi, H., Matyas, J. R., Ponjevic, D., & Sutherland, G. R.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-10-19
- Volume
- 14
- Issue
- 1
- Pages
- 53-63
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2108402757
- Cited by
- 192
- References
- 1
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging. https://app.cochat.ai/papers/10.1093/neuonc/nor183
- The paper
- Tomanek, B., Iqbal, U., Blasiak, B., Abulrob, A., Albaghdadi, H., Matyas, J. R., Ponjevic, D., & Sutherland, G. R. (2012). Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging. Neuro-Oncology. https://doi.org/10.1093/neuonc/nor183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.